Glaucoma tx Taflotan demonstrates long-term effectiveness

Comparative Analysis of Prostaglandin (PGA) Formulation for the First Time in Korea

Maintaining visual damage suppression and reduced eye pressure, similar level to PGA

Santen (CEO Lee Han-woong) announced on the 21st that an open-angle glaucoma high-pressure treatment called Taflotan has confirmed the effects of long-term intraocular pressure lowering and glaucoma inhibition in comparison with PGA.

 

The results of the PGA analysis were published in the Journal of Clinical Medicine.

 

The LOTUS study is the first multi-organ retrospective cohort study that compares and analyzes the long-term effects and safety profiles of PGA, the primary treatment for glaucoma, in Korean patients.

 

From January 2010 to June 2016, we evaluated the progression of visual impairment and the effect of reduced intraocular pressure on primary glaucoma or normal intraocular glaucoma patients, including Taflotan, Latanoprost, and Travoprost.

 

Based on electronic medical records (EMR), the patient group was classified into primary glaucoma or normal eye pressure glaucoma group (216 patients) and normal eye pressure glaucoma group (177 patients).

 

The study found that the MD Slope in the Taflotan treatment group remained stable for a long time in the early open-angle glaucoma or early normal eye pressure glaucoma, similar to that in the case of administration of Latanoprost and Travoprost.

 

Measurements of eye pressure changes after administration of Taflotan showed a decrease of -1.89±2.77mmHg in the primary open angle glaucoma or normal intraocular pressure glaucoma group and -2.20±2.64mmHg in the normal intraocular pressure glaucoma group.

 

The reduced eye pressure remained stable for a long time.

 

The effects between the three PGA's were identified at similar levels in both patient groups, with no significant adverse reactions.

 

Glaucoma is a disease in which the optic nerve becomes weaker due to increased intraocular pressure, and it is fatal because it can lead to blindness.

 

Glaucoma is divided into open-angle glaucoma and angle-closure glaucoma, one of the most common types of open-angle glaucoma in domestic glaucoma, depending on whether the discharge passage for waterproofing the eye pressure is open.

 

Normal eye pressure glaucoma is within the normal range of 21mmHg or less, but active drug treatment is needed because the optic nerve is vulnerable and easily damaged.

 

PGA is the drug family with the highest intraocular pressure drop effect among glaucoma single drugs developed so far, and is most often used as a primary treatment for glaucoma due to its high patient conformity and little systemic side effects.

 

"LOTUS research is meaningful in that it compares the long-term effects and safety profiles of PGA, which are most commonly used in glaucoma treatment, for the first time in Korea," said Kim Joon-mo, an ophthalmologist at Sungkyunkwan University's medical school.

 

"In particular, we expect that it will help patients preserve their vision and vision from an early stage, as the glaucoma progression of Taflotan-only treatment has been confirmed to be equivalent to that of the existing PGA," he said.

 

Meanwhile, Taflotan is a glaucoma treatment released by Santen in 2010 and is available for patients with open-angle glaucoma and ocular hypertension, including normal eye pressure glaucoma.